Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.
VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.
Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).
Biodesix, Inc., today announced the relocation of their corporate headquarters from Broomfield, Colorado to Boulder, Colorado.
Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.
Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.
Biodesix received the Product Differentiation Excellence Award for its accomplishments in the cancer diagnostics industry.
A retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual San Antonio Breast Cancer Symposium SABCS.
Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.
BioConference Live has selected Biodesix to present at the 5th annual Life Sciences conference, taking place online on October 26–27.